|
Market Closed -
Nasdaq
04:00:00 2025-05-20 pm EDT
|
5-day change | 1st Jan Change | ||
| 9.600 USD | -1.13% |
|
-.--% | - |
| 25-05-22 | OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P Global BMI Index | CI |
| 25-05-22 | OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P TMI Index | CI |
| Market Cap | 97.22M 86.87M 81.05M 73.62M 139M 9.4B 140M 974M 380M 4.78B 365M 357M 15.38B | P/E 2023 |
-4.07x | P/E 2024 | -3.15x |
|---|---|---|---|---|---|
| Enterprise Value | 142M 127M 118M 107M 202M 13.71B 204M 1.42B 555M 6.97B 532M 520M 22.41B | EV / Sales 2023 |
2.86x | EV / Sales 2024 | 1.43x |
| Free-Float |
6.21% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -1.13% |
| 3 years | 4.81 |  | 31.5 |
| 5 years | 4.81 | | 64.5 |
| 10 years | 4.81 | | 450 |
| Manager | Title | Age | Since |
|---|---|---|---|
Evan Loh
CEO | Chief Executive Officer | 67 | 2025-05-20 |
| Chief Tech/Sci/R&D Officer | - | 2019-12-31 | |
Jonathan Neely
IRC | Investor Relations Contact | - | 2020-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Evan Loh
BRD | Director/Board Member | 67 | 2025-05-20 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/21/25 | Issuer sale | Chief Financial Officer | 82,491 | 0.8204% | ||
| 5/21/25 | Issuer sale | Director | 12,624 | 0.1255% | ||
| 5/21/25 | Issuer sale | Director | 12,624 | 0.1255% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -.--% | -.--% | -48.80% | 97.22M | |
| +2.70% | +2.73% | +40.91% | +110.31% | 1,060B | |
| +1.44% | -2.38% | +36.83% | +63.95% | 623B | |
| +1.75% | +3.73% | +16.55% | +83.05% | 480B | |
| +0.60% | -1.73% | +62.98% | +37.46% | 352B | |
| -1.88% | +1.26% | +21.32% | +40.88% | 345B | |
| -1.30% | +0.32% | +11.21% | +34.39% | 274B | |
| -1.23% | -1.86% | -5.70% | +11.02% | 249B | |
| +2.60% | -2.00% | +39.77% | +54.44% | 223B | |
| +1.82% | -1.48% | +25.75% | +96.48% | 182B | |
| Average | -0.67% | -0.44% | +24.96% | +48.32% | 378.81B | |
| Weighted average by Cap. | -0.50% | +0.04% | +31.41% | +70.15% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 70.99M 63.43M 59.18M 53.75M 101M 6.87B 102M 711M 278M 3.49B 266M 261M 11.23B | 78.23M 69.89M 65.21M 59.23M 112M 7.57B 112M 784M 306M 3.85B 294M 287M 12.37B |
| Net income | -35.48M -31.7M -29.58M -26.87M -50.6M -3.43B -50.98M -355M -139M -1.75B -133M -130M -5.61B | -21.54M -19.25M -17.96M -16.31M -30.72M -2.08B -30.95M -216M -84.3M -1.06B -80.87M -79.12M -3.41B |
| Net Debt | 58.06M 51.88M 48.4M 43.97M 82.8M 5.62B 83.42M 582M 227M 2.86B 218M 213M 9.18B | 44.48M 39.74M 37.08M 33.68M 63.42M 4.3B 63.9M 446M 174M 2.19B 167M 163M 7.03B |
Employees
128
Sector
Pharmaceuticals
- Stock Market
- Stocks
- OPTN Stock
Select your edition
All financial news and data tailored to specific country editions
